Health CanadaGeneral Alert
Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR...
Published: January 12, 2022Recall ID: 62311Category: generalCountry: Canada
Reason for Recall / Hazard
Product safety
Product Description & Identification
Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer
Affected Products
Xeljanz and Xeljanz XR (tofacitinib), a prescription drug used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.
Additional Source Details
| Field | Value |
|---|---|
| N I D | 62311 |
| U R L | https://recalls-rappels.canada.ca/en/alert-recall/health-canada-safety-review-finds-link-between-use-xeljanz-and-xeljanz-xr-tofacitinib |
| Issue | Product safety |
| Title | Health Canada safety review finds link between the use of Xeljanz and Xeljanz XR (tofacitinib) and increased risk of serious heart-related issues and cancer |
| Product | Xeljanz and Xeljanz XR (tofacitinib), a prescription drug used to treat rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. |
| Archived | 0 |
| Category | Drugs |
| Last updated | 2022-01-12 |
| Organization | Communications and Public Affairs Branch |